4[2]Scheiman MM, Levine JH, Cannom DS, et al. Dose-Ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation, 1995;92:3264
5[3]Schmidt A, Konig W, Binner L, et al. Efficacy and safety of intravenous amiodarone inacute refractory arrhythmias. Clin Cardiol, 1998; 11: 481
6[1]Mukharji J, Rude RE, Poole WR, et al. Risk factors for sudden death after acute myocardial infarction: two-year followup[J]. AmJCardiol, 1984,54:31-36.
7[2]Cardiac Arrhythmia Suppression Trial(CAST)Investigators. Porelininary report:effect of encainide and flecainide on mor tality in a randomized trial of arrhythmia suppression after myocardial infarction [J], N Engl J med, 1989,321: 406- 412.
8[3]Cardiac Arrhythmia Suppression Ⅱ Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocar dial infarction[J]. N Engl J Med 1992,327: 227-233.
9[4]Lazzara R. Foom first calss to third class:Recent upheaval in antiarrhythmic therapy-lessons from clinical trials[J]. Am J Cardiol, 1996,78(Suppl 4A) :28.
10[5]Podrid PJ. Amiodarone: Reevaluation of an old drug[J].Ann Intern Med, 1995,122:689.
